Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
38%(3 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_2
3
25%
Ph phase_1
3
25%
Ph phase_3
1
8%
Ph phase_4
1
8%

Phase Distribution

3

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(3)
Other(1)

Detailed Status

Completed8
Terminated2
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 31 (12.5%)
Phase 41 (12.5%)

Trials by Status

completed867%
withdrawn18%
terminated217%
unknown18%

Recent Activity

0 active trials
Showing 5 of 12
completed

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

NCT07036809
completed

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

NCT04651400
terminatedphase_2

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
completed

Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO

NCT04879550
withdrawnphase_1

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

NCT04055389
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07036809

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

Completed
NCT04651400

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

Completed
NCT04899232Phase 2

Antithrombin III in Infectious Disease Caused by COVID-19

Terminated
NCT04879550

Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO

Completed
NCT04055389Phase 1

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

Withdrawn
NCT04912193

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

Completed
NCT02103114Phase 2

Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery

Completed
NCT02631174Phase 1

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

Completed
NCT00823082Phase 2

Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass

Completed
NCT01698567Phase 1

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

Terminated
NCT01530737Phase 3

Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery

Completed
NCT01201070Phase 4

Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
12